Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in Bethesda, MD. The poster detailed two important observations that support Cassava’s plan to initiate human clinical studies in H1 2026 to evaluate simufilam as a treatment for Tuberous Sclerosis Complex-related epilepsy: Preclinical proof-of-concept: Treatment with simufilam alleviated neuronal abnormalities and reduced seizure frequency by 60% compared to vehicle in a mouse model of focal onset seizures. Clinical safety: Data from two human Phase 3 studies in Alzheimer’s disease demonstrated a favorable safety profile.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.